Table 4.
Clinical outcomes of included studies.
| Study | Follow-Up | Treatment and Subgroup | IKDC | WOMAC | VAS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| chung 2021 [23] | mean 1.7 Y (1.0–3.5) | hUCB-MSC | pre | final | pre | final | N/A | ||||||||||
| 39.0 ± 10.4 | 71.3 ± 5.9 | 44.5 ± 15.1 | 11.0 ± 3.7 | ||||||||||||||
| song (1) 2020 [19] | 36.1 ± 6.4 M (25–47) | hUCB-MSC | pre | 1 Y | final | pre | 1 Y | final | pre | 1 Y | final | ||||||
| 32.5 ± 8.3 | 55.8 ± 14.3 | 61.2 ± 17.2 | 39.3 ± 12.2 | 17.2 ± 12.7 | 13.9 ± 14.1 | 7.0 ± 1.6 | 2.5 ± 1.7 | 2.0 ± 2.1 | |||||||||
| song (2) 2020 [18] | 3 Y | hUCB-MSC | pre | 1 Y | 2 Y | 3 Y | pre | 1 Y | 2 Y | 3 Y | pre | 1 Y | 2 Y | 3 Y | |||
| trochlear lesion | 29.3 ± 7.3 | 56.7 ± 9.7 | 61.6 ± 10.7 | 64.7 ± 11 | 44.8 ± 10.3 | 13.8 ± 7.5 | 10.7 ± 6.9 | 8.4 ± 6.4 | 7.8 ± 1.2 | 2.6 ± 1.7 | 2.1 ± 1.5 | 1.6 ± 1.4 | |||||
| no trochlear lesion | 28.5 ± 7.6 | 56.7 ± 9.7 | 61.4 ± 9.5 | 65.3 ± 11.4 | 43.1 ± 11.1 | 13.2 ± 8.2 | 11.3 ± 8.5 | 8.4 ± 6.8 | 7.3 ± 1.3 | 2.3 ± 1.6 | 2.0 ± 1.7 | 1.4 ± 1.6 | |||||
| song (3) 2020 [21] | 26.7 ± 1.8 (24–31) |
hUCB-MSC | pre | 1 Y | 2 Y | pre | 1 Y | 2 Y | pre | 1 Y | 2 Y | ||||||
| 24.3 ± 11.1 | 58.9 ± 10.3 | 68.5 ± 12.7 | 57.3 ± 11.4 | 15.6 ± 9.6 | 10.2 ± 7.9 | 76.4 ± 16.6 | 20.4 ± 15.1 | 12.8 ± 11.7 | |||||||||
| Lee 2021 [22] | pre | final | |||||||||||||||
| 20.7 ± 6.1 M | BMAC | N/A | 43.9 ± 12.7 | 23.4 ± 11.6 | N/A | ||||||||||||
| 15.6 ± 2.8 M | hUCB-MSC | N/A | 45.2 ± 8.8 | 19.5 ± 15.8 | N/A | ||||||||||||
| Ryu 2022 [20] | pre | final | pre | final | |||||||||||||
| 2 Y | BMAC | 44.17 ± 12.5 | 80.27 ± 9.48 | N/A | 5.2 ± 1.1 | 0.92 ± 0.98 | |||||||||||
| hUCB-MSC | 42.02 ± 13.63 | 81.35 ± 11.07 | N/A | 5.0 ± 1.2 | 0.85 ± 0.86 | ||||||||||||
| Study | Follow-up | Treatment and Subgroup | IKDC | WOMAC | VAS | ||||||||||||
| Lim 2021 [17] | pre | 48 weeks | 3 Y | 4 Y | 5 Y | pre | 48 weeks | 3 Y | 4 Y | 5 Y | pre | 48 weeks | 3 Y | 4 Y | 5 Y | ||
| 5 Y | microfracture | 41.8 ± 13.4 | 53.5 (48.5 to 58.5) |
49.0 (43.3 to 54.7) |
48.9 (42.1 to 55.7) |
47.1 (41.1 to 53.2) |
40.4 ± 14.8 | 26.2 (21.1 to 31.2) |
34.5 (27.2 to 41.8) |
35.8 (27.6 to 44.1) |
36.2 (28.6 to 43.8) |
44.6 ± 12.9 | 24.1 (18.3 to 29.9) |
41.1 (32.2 to 50.0) |
43.3 (34.7 to 51.8) |
43.5 (35.3 to 51.6) |
|
| hUCB-MSC | 42.7 ± 13.9 | 53.4 (49.0 to 57.8) |
57.4 (50.8 to 64.1) |
53.7 (48.2 to 59.3) |
54.7 (48.7 to 60.7) |
37.4 ± 15.1 | 24.7 (20.5 to 28.9) |
25.4 (19.9 to 31.0) |
28.6 (22.4 to 34.9) |
26.9 (20.4 to 33.5) |
44.0 ± 12.5 | 24.2 (17.5 to 31.0) |
30.9 (23.6 to 38.2) |
35.7 (29.2 to 42.3) |
29.1 (22.4 to 35.8) |
||
Y = year, M = month, hUCB-MSC = human umbilical cord blood derived mesenchymal stem cell, BMAC = bone marrow aspiration concentrate, IKDC = International Knee Documentation Committee score, WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index, VAS = visual analogue scale, pre = preoperative, final = final follow-up.